The antiserum was produced against synthesized peptide derived from human IKK-beta around the phosphorylation site of Tyr199. AA range:166-215

Phospho-IKKβ (Y199) Polyclonal Antibody detects endogenous levels of IKKβ protein only when phosphorylated at Y199.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):QKyTV

IKBKB

Inhibitor of nuclear factor kappa-B kinase subunit beta

IKBKB ;
IKKB ;
Inhibitor of nuclear factor kappa-B kinase subunit beta ;
I-kappa-B-kinase beta ;
IKK-B ;
IKK-beta ;
IkBKB ;
I-kappa-B kinase 2 ;
IKK2 ;
Nuclear factor NF-kappa-B inhibitor kinase beta ;
NFKBIKB

The protein encoded by this gene phosphorylates the inhibitor in the inhibitor/NF-kappa-B complex, causing dissociation of the inhibitor and activation of NF-kappa-B. The encoded protein itself is found in a complex of proteins. Several transcript variants, some protein-coding and some not, have been found for this gene. [provided by RefSeq, Sep 2011],

Catalytic activity:ATP + [I-kappa-B protein] = ADP + [I-kappa-B phosphoprotein].,Function:Acts as part of the IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. Also phosphorylates NCOA3.,PTM:Ubiquitination on 'Ser-163' modulates phosphorylation on C-terminal serine residues.,PTM:Upon cytokine stimulation, phosphorylated on Ser-177 and Ser-181 by MEKK1 and/or MAP3K14/NIK; which enhances activity. Once activated, autophosphorylates on the C-terminal serine cluster; which decreases activity and prevents prolonged activation of the inflammatory response.,PTM:Yersinia yopJ may acetylate Ser/Thr residues, preventing phosphorylation and activation, which blocks the I-kappa-B signaling pathway.,similarity:Belongs to the protein kinase superfamily. Ser/Thr protein kinase family. I-kappa-B kinase subfamily.,similarity:Contains 1 protein kinase domain.,subunit:Component of the I-kappa-B-kinase (IKK) core complex consisting of CHUK, IKBKB and IKBKG; probably four alpha/CHUK-beta/IKBKB dimers are associated with four gamma/IKBKG subunits. The IKK core complex seems to associate with regulatory or adapter proteins to form a IKK-signalosome holo-complex. Part of a complex composed of NCOA2, NCOA3, CHUK/IKKA, IKBKB, IKBKG and CREBBP. Part of a 70-90 kDa complex at least consisting of CHUK/IKKA, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14. Interacts with SQSTM1 through PRKCZ or PRKCI. Forms an NGF-induced complex with IKBKB, PRKCI and TRAF6. May interact with MAVS/IPS1. Interacts with NALP2. Interacts with TICAM1. Interacts with Yersinia yopJ. Interacts with FAF1; the interaction disrupts the IKK complex formation. Interacts with ATM. Part of a ternary complex consisting of TANK, IKBKB and IKBKG. Interacts with NIBP; the interaction is direct.,tissue specificity:Highly expressed in heart, placenta, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis and peripheral blood.,

Cytoplasm . Nucleus . Membrane raft . Colocalized with DPP4 in membrane rafts. .

Highly expressed in heart, placenta, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis and peripheral blood.

>>Antifolate resistance ;
>>MAPK signaling pathway ;
>>Ras signaling pathway ;
>>Chemokine signaling pathway ;
>>NF-kappa B signaling pathway ;
>>FoxO signaling pathway ;
>>mTOR signaling pathway ;
>>PI3K-Akt signaling pathway ;
>>Apoptosis ;
>>Osteoclast differentiation ;
>>Toll-like receptor signaling pathway ;
>>NOD-like receptor signaling pathway ;
>>RIG-I-like receptor signaling pathway ;
>>Cytosolic DNA-sensing pathway ;
>>C-type lectin receptor signaling pathway ;
>>IL-17 signaling pathway ;
>>Th1 and Th2 cell differentiation ;
>>Th17 cell differentiation ;
>>T cell receptor signaling pathway ;
>>B cell receptor signaling pathway ;
>>TNF signaling pathway ;
>>Neurotrophin signaling pathway ;
>>Insulin signaling pathway ;
>>Adipocytokine signaling pathway ;
>>Type II diabetes mellitus ;
>>Insulin resistance ;
>>Non-alcoholic fatty liver disease ;
>>Alcoholic liver disease ;
>>Alzheimer disease ;
>>Epithelial cell signaling in Helicobacter pylori infection ;
>>Pathogenic Escherichia coli infection ;
>>Shigellosis ;
>>Salmonella infection ;
>>Yersinia infection ;
>>Chagas disease ;
>>Toxoplasmosis ;
>>Hepatitis C ;
>>Hepatitis B ;
>>Measles ;
>>Human cytomegalovirus infection ;
>>Influenza A ;
>>Human papillomavirus infection ;
>>Human T-cell leukemia virus 1 infection ;
>>Kaposi sarcoma-associated herpesvirus infection ;
>>Herpes simplex virus 1 infection ;
>>Epstein-Barr virus infection ;
>>Human immunodeficiency virus 1 infection ;
>>Coronavirus disease - COVID-19 ;
>>Pathways in cancer ;
>>MicroRNAs in cancer ;
>>Chemical carcinogenesis - reactive oxygen species ;
>>Pancreatic cancer ;
>>Prostate cancer ;
>>Chronic myeloid leukemia ;
>>Acute myeloid leukemia ;
>>Small cell lung cancer ;
>>PD-L1 expression and PD-1 checkpoint pathway in cancer ;
>>Lipid and atherosclerosis ;
>>Fluid shear stress and atherosclerosis